Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
abacavir + lamivudine + lopinavir + ritonavir
- Development stage
- Phase 4
- Lead developer
- Drugs for Neglected Diseases initiative
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Abacavir + lamivudine + lopinavir + ritonavir** is a paediatric, strawberry-flavoured, heat-stable oral fixed-dose antiretroviral combination for treatment of HIV-1 infection. It combines the nucleoside reverse transcriptase inhibitors abacavir and lamivudine with lopinavir, an HIV-1 protease inhibitor, and ritonavir, which both inhibits HIV protease and pharmacokinetically boosts lopinavir by inhibiting CYP3A-mediated metabolism. The formulation was developed by Drugs for Neglected Diseases initiative and Cipla as granules contained in capsules for infants and young children who cannot swallow tablets.
- Brand names
- Quadrimune
- Other names
- 4-in-1ABC/3TC/LPV/rabacavir/lamivudine/lopinavir/ritonavirlopinavir/ritonavir + abacavir/lamivudine
02
Targets
CYP3A4 (Cytochrome P450 3A4)PR (Progesterone receptor)Human immunodeficiency virus type 1 reverse transcriptase
Beyond the preview
Go deeper on abacavir + lamivudine + lopinavir + ritonavir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on abacavir + lamivudine + lopinavir + ritonavir.